Expert Opinion on Therapeutic Patents最新文献

A patent review of VEGFR-2 inhibitors: an update (2022 - present). VEGFR-2抑制剂的专利审查：更新（2022年至今）。

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-05-01 Epub Date: 2026-04-26 DOI: 10.1080/13543776.2026.2660910

Thoraya A Farghaly, Marwa F Harras, Amani M R Alsaedi, Sami A Al-Hussain, Nadia T Al-Qurashi, Sayed M Riyadh, Magdi E A Zaki, Shadia M Hussein

{"title":"A patent review of VEGFR-2 inhibitors: an update (2022 - present).","authors":"Thoraya A Farghaly, Marwa F Harras, Amani M R Alsaedi, Sami A Al-Hussain, Nadia T Al-Qurashi, Sayed M Riyadh, Magdi E A Zaki, Shadia M Hussein","doi":"10.1080/13543776.2026.2660910","DOIUrl":"10.1080/13543776.2026.2660910","url":null,"abstract":"Introduction: A complicated process called angiogenesis creates new blood vessels from existing ones. Oxygen and nutrients from angiogenesis support tumor development, invasion, and metastasis. Many biological agents cause angiogenesis. EGF, FGF, VEGF, transcription factors, cytokines, adhesion molecules, proteinases, and growth factors. VEGF-A, B, C, and D are necessary for angiogenesis. VEGF family members interact with VEGFR-1,-2, and-3. Overexpression of VEGF proteins and receptors occurs during cancer progression. Novel signaling pathways, transcription factors, and mechanisms may help cure cancers by inhibiting angiogenesis.Areas covered: This review discusses VEGFR-2 inhibitors patented since 2022 and their potential use in the management of angiogenesis-related disorders like cancer.Expert opinion: Small-molecule VEGFR-2 inhibitors have minimal selectivity and cause fatigue, anorexia, hypertension, hemorrhage, and bleeding due to their affinity for PDGF, EGFR, and RAF, which is conserved in many tyrosine kinases. Poor pharmacokinetics, side effects, and high manufacturing costs may limit biomolecule adoption despite clinical success. Proangiogenic and non-tumor proangiogenic chemicals and myeloid cells produced treatment resistance. Thus, multimodal targeted medications or combination therapy with anti-angiogenic therapies, chemotherapeutic agents, immune checkpoint inhibitors, or gene therapy are needed to block pathological angiogenesis and increase selectivity, safety, diagnosis, and therapy response.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"435-458"},"PeriodicalIF":4.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present). 激活素受体样激酶5 （ALK5）抑制剂：专利审查（2013年至今）。

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-05-01 Epub Date: 2026-04-19 DOI: 10.1080/13543776.2026.2660906

Xin-Yi Huang, Chao-Qun Yu, Xin Wang, Zhen Guo, Cheng-Hua Jin

{"title":"Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present).","authors":"Xin-Yi Huang, Chao-Qun Yu, Xin Wang, Zhen Guo, Cheng-Hua Jin","doi":"10.1080/13543776.2026.2660906","DOIUrl":"10.1080/13543776.2026.2660906","url":null,"abstract":"Introduction: Activin receptor-like kinase 5 (ALK5) is a pivotal component of the transforming growth factor β (TGF-β) signaling pathway. Currently, 10 ALK5 inhibitors are under clinical investigation, with numerous others in preclinical stages, demonstrating broad therapeutic potential. However, no systematic review of ALK5 inhibitor-related patents has been conducted to date. Therefore, this study systematically reviews patents related to ALK5 inhibitors from 2013 to the present, providing a theoretical basis for discovering structurally novel, safe, and effective ALK5 inhibitors.Areas covered: This paper briefly outlines ALK5 inhibitors currently in clinical development and ALK5-related patents published since 2013, retrieved through databases such as Google Patents, CAS SciFinder and PatSnap.Expert opinion: ALK5 inhibitors have garnered significant interest in recent years for the treatment of TGF-β-related diseases, with encouraging outcomes observed in clinical trials. However, certain structural classes have been associated with adverse effects such as cardiotoxicity and bone toxicity. This review consolidates patent literature on ALK5 inhibitors, offering insights to support the development of novel, highly efficient, and low-toxicity inhibitors with improved pharmacokinetic profiles.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"401-433"},"PeriodicalIF":4.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present). NLRP3抑制剂治疗炎症性疾病的专利审查（2023年至今）。

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-05-01 Epub Date: 2026-04-10 DOI: 10.1080/13543776.2026.2656161

Jannatun N Namme, Yiming Xu, Elijah McClendon, Can Zhang, Shijun Zhang

{"title":"A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present).","authors":"Jannatun N Namme, Yiming Xu, Elijah McClendon, Can Zhang, Shijun Zhang","doi":"10.1080/13543776.2026.2656161","DOIUrl":"10.1080/13543776.2026.2656161","url":null,"abstract":"Introduction: With increasing knowledge and understanding of the molecular mechanisms of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome and its role in inflammatory diseases, NLRP3 has emerged as a highly druggable target. This is reflected in extensive efforts to develop small molecule NLRP3 inhibitors with diverse chemical scaffolds and mechanisms of action (MOAs), aimed to achieve disease intervention.Areas covered: The current review summarizes recent patents on NLRP3 inhibitor development from 2023 to present. In addition, the molecular mechanisms underlying NLRP3 activation and its involvement in inflammatory diseases were also discussed. The second objective is to get a comprehensive analysis of currently available patent applications and priority filings on NLRP3-targeted therapies with emphasis on new indications.Expert opinion: This review provides an organized, systematic, and coherent overview of recent progress in NLRP3-targeted therapeutics and highlights the increasing diversity of chemical classes of new NLRP3 inhibitors, as well as the overall trend toward increased strategic activity across patent jurisdictions and territories.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"471-484"},"PeriodicalIF":4.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147616147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes. 肥胖和2型糖尿病的双重GLP-1/胰高血糖素受体激动剂Mazdutide的专利前景和治疗进展。

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-05-01 Epub Date: 2026-03-29 DOI: 10.1080/13543776.2026.2645812

Mohammed Abdul Fasi

{"title":"Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.","authors":"Mohammed Abdul Fasi","doi":"10.1080/13543776.2026.2645812","DOIUrl":"10.1080/13543776.2026.2645812","url":null,"abstract":"Introduction: Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes. While its clinical efficacy is increasingly recognized, the intellectual property framework that underpins its development and long-term positioning has not been systematically examined.Areas covered: This review presents a comprehensive patent landscape analysis of mazdutide and related oxyntomodulin analogs. Patent documents were identified using the Patentscope database, covering filings between 2015 and 2025. Twelve patent families were analyzed, encompassing composition-of-matter, process chemistry, formulation technologies, dosing regimens, and therapeutic applications. The analysis traces the evolution of innovation from early peptide design by Eli Lilly to later formulation, clinical, and indication-expansion strategies led by Innovent Biologics, including obesity, type 2 diabetes, hyperuricemia, and adolescent obesity.Expert opinion: Mazdutide illustrates how layered patent strategies integrating molecular design, manufacturability, formulation stability, and clinical use claims can secure durable exclusivity. This approach provides a strategic model for future dual and multi-receptor peptide therapeutics.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"459-469"},"PeriodicalIF":4.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147443023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patents involving monoamine oxidase (MAO): a comprehensive update (2022-2025) on its inhibitors and applications. 涉及单胺氧化酶（MAO）的专利：其抑制剂和应用的全面更新（2022-2025）。

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-04-01 Epub Date: 2026-02-25 DOI: 10.1080/13543776.2026.2633345

Moataz A Shaldam, Simone Carradori, Marwa Balaha, Paolo Guglielmi, Francesca Diomede, Ilaria D'Agostino, Haytham O Tawfik

{"title":"Patents involving monoamine oxidase (MAO): a comprehensive update (2022-2025) on its inhibitors and applications.","authors":"Moataz A Shaldam, Simone Carradori, Marwa Balaha, Paolo Guglielmi, Francesca Diomede, Ilaria D'Agostino, Haytham O Tawfik","doi":"10.1080/13543776.2026.2633345","DOIUrl":"10.1080/13543776.2026.2633345","url":null,"abstract":"Introduction: Monoamine oxidases (MAOs) A and B are key enzymes for the oxidative deamination of monoamine neurotransmitters, including dopamine, serotonin, norepinephrine, and tyramine. Selective MAO-B inhibitors are clinically employed as adjuvant therapies for neurodegenerative disorders, whereas selective MAO-A inhibitors are mainly considered third-line options in the treatment of depression. However, due to their function in regulating synaptic activity and exogenous monoamine metabolism, research in this field is continually expanding.Areas covered: This review summarizes patents on MAO inhibitors between 2022 and 2025. For the most investigated chemotypes (14 synthetic cores along with compounds from natural sources), biological activities were analyzed. The compounds are divided into two main categories, naturally occurring molecules and newly synthesized derivatives, with a total of 114 compounds discussed. To provide a more comprehensive perspective on the therapeutic potential of these inhibitors, additional treatment alternatives are also outlined.Expert opinion: Recently patented MAO inhibitors show notable properties, including significant isoform selectivity and therapeutic potential toward other diseases, such as fibromyalgia, CDKL5-deficient disorder, neuropathic pain, and Alzheimer's disease.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"363-387"},"PeriodicalIF":4.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

5'-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present). 5'-外核苷酸酶（CD73）抑制剂：专利审查（2021年至今）。

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-04-01 Epub Date: 2026-03-05 DOI: 10.1080/13543776.2026.2638344

Zhaolin Wang, Anna Junker

{"title":"5'-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present).","authors":"Zhaolin Wang, Anna Junker","doi":"10.1080/13543776.2026.2638344","DOIUrl":"10.1080/13543776.2026.2638344","url":null,"abstract":"Introduction: Adenosine-mediated immunosuppression is a major mechanism of tumor immune escape and is largely driven by ecto-5'-nucleotidase (CD73), which catalyzes the formation of extracellular adenosine and limits the efficacy of cancer immunotherapies. Consequently, CD73 has emerged as a key immune checkpoint and an attractive target for therapeutic and diagnostic intervention.Areas covered: This review summarizes patent literature on CD73 inhibitors published from 2021 to the present. The analysis covers advances in nucleotide-derived inhibitors, including structure-guided optimization and strategies enabling peroral bioavailability, as well as the maturation of non-nucleotide small-molecule inhibitors with alternative binding modes. In addition, CD73-targeted antibodies, nanobodies, and positron emission tomography (PET) tracers are discussed in the context of translational development, patient stratification, and combination therapy. Patent databases were systematically surveyed to identify relevant disclosures and emerging trends.Expert opinion: Recent patents indicate a shift from maximizing enzymatic potency toward balanced optimization of potency, pharmacokinetics, and combinatorial compatibility. Perorally bioavailable small molecules and CD73-targeted imaging agents are positioning CD73 inhibition as a mature and versatile therapeutic and theranostic strategy.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"389-400"},"PeriodicalIF":4.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147304022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LSD1 inhibitors for anticancer therapy: an updated patent review (2022-2025). 用于抗癌治疗的LSD1抑制剂：更新的专利审查（2022-2025）

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-04-01 Epub Date: 2026-02-26 DOI: 10.1080/13543776.2026.2636040

Zhoudong Zhang, Jiyu Li, Zitong Wang, Jiayi Zhou, Xiaolu Xiong, Wenjie Hou, Huanqiu Li

{"title":"LSD1 inhibitors for anticancer therapy: an updated patent review (2022-2025).","authors":"Zhoudong Zhang, Jiyu Li, Zitong Wang, Jiayi Zhou, Xiaolu Xiong, Wenjie Hou, Huanqiu Li","doi":"10.1080/13543776.2026.2636040","DOIUrl":"10.1080/13543776.2026.2636040","url":null,"abstract":"Introduction: Lysine-specific demethylase 1 (LSD1) is a key epigenetic enzyme relying on flavin adenine dinucleotide to regulate gene expression via histone H3 demethylation and non-histone substrate modification. Discovered in 2004, it overturned the view that histone modifications are irreversible. Abnormal LSD1 overexpression drives solid tumor and hematological malignancy initiation, progression, and drug resistance, making it a key oncology target.Areas covered: This review discusses recent innovations in LSD1 inhibitor development, focusing on small-molecule patents published from 2022 to 2025. A systematic search of SciFinder, Derwent Innovation, and WIPO databases was conducted for this period. It categorizes these novel inhibitors into six classes and summarizes their structural features, biological data, design strategies and LSD1 interaction mechanisms.Expert opinion: In recent years, LSD1 inhibitors have demonstrated structural diversification, innovative mechanisms, and expanded indications. Concurrently, breakthroughs have been achieved in optimizing structure, mechanism of action, dual-target strategies, selectivity and safety, and indications. Future efforts should focus on further validating dual-target strategies, and elucidating binding mechanisms to advance their application as a core targeted therapy in epigenetics for more malignant tumors therapy.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"311-332"},"PeriodicalIF":4.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present). 因子XII(a)抑制剂的最新进展：更新的专利格局（2020年至今）

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-04-01 Epub Date: 2026-02-19 DOI: 10.1080/13543776.2026.2627911

Dmitrii V Kalinin

{"title":"Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present).","authors":"Dmitrii V Kalinin","doi":"10.1080/13543776.2026.2627911","DOIUrl":"10.1080/13543776.2026.2627911","url":null,"abstract":"Introduction: Factor XII (FXII) is a liver-derived plasma zymogen that autoactivates on anionic surfaces to FXIIa, which drives the contact blood coagulation pathway, kallikrein-kinin signaling, fibrinolysis, and classical complement. Although congenital FXII(a) deficiency is largely asymptomatic, dysregulated activity is linked to thrombosis, hereditary angioedema (HAE), and neuroinflammation, making FXII(a) an attractive therapeutic target.Areas covered: This review provides a brief overview of FXII/FXIIa structure and function to highlight its suitability as a therapeutic target. It then summarizes patents published between 2020 and 2025 (patent search using Espacenet, Google Patents, and SciFinder) covering FXII(a)-targeting agents across diverse modalities, including small molecules, proteins and peptides, monoclonal antibodies, oligonucleotides, and siRNAs.Expert opinion: Patent analysis indicates that most FXII(a) inhibitors remain in early preclinical development, though a growing subset has shown in vivo efficacy in models of thrombosis, HAE, sepsis, and neuroinflammation. The breadth and pace of 2020-2025 filings, together with accumulating translational data, should accelerate progression from patents to clinical candidates, particularly for contact-activation indications (e.g. device-related thrombosis). Resolving full-length FXII/α-FXIIa structures would further enable allosteric inhibitors design.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"333-361"},"PeriodicalIF":4.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146117937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated patent review of isoflavones and isocoumarins (2018-2024). 异黄酮和异香豆素专利更新审查（2018-2024）。

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-04-01 Epub Date: 2026-03-10 DOI: 10.1080/13543776.2026.2642104

Hidayat Hussain

{"title":"An updated patent review of isoflavones and isocoumarins (2018-2024).","authors":"Hidayat Hussain","doi":"10.1080/13543776.2026.2642104","DOIUrl":"10.1080/13543776.2026.2642104","url":null,"abstract":"Introduction: It is well established that isocoumarins and isoflavones exhibit intriguing biological effects. During the period 2018-2024 isocoumarins and isoflavones chemistry has attracted attention due to their biological and pharmaceutical properties.Areas covered: This review focuses on patents relating to the therapeutic properties of isocoumarins and isoflavones between 2018 and 2024. The latest patented studies of isocoumarin and isoflavone are summarized by using the keywords 'isocoumarin' and 'isoflavone' in SciFinder, PubMed, and Google Patents databases in the year from 2018 to 2024.Expert opinion: A wide range of important pharmaceutical properties are exhibited by isocoumarins and isoflavones and their synthetic analogs. In addition, isocoumarins and isoflavones have the potential to couple with other biologically active molecules, synergistically enhancing delivery and biological effects. In addition, scientists should direct their efforts toward the synthesis of halo-substituted and functionalized heterocyclic ring derivatives of isocoumarins and isoflavones, with a view to obtaining lead compounds. The lack of pharmacology and pharmacokinetics data along with in vivo studies for isocoumarins and isoflavones, prevents effective regulatory decisions from being proposed. In addition, detailed efficacy studies in well-established disease models are required to determine the clinical effects of isocoumarins and isoflavones.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"299-309"},"PeriodicalIF":4.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel fatty acid amide hydrolase (FAAH) inhibitors: a patent review from 2015 to 2025. 新型脂肪酸酰胺水解酶（FAAH）抑制剂：2015 - 2025年专利审查

IF 4.6 2区医学

Expert Opinion on Therapeutic Patents Pub Date : 2026-03-01 Epub Date: 2026-02-04 DOI: 10.1080/13543776.2026.2619515

Laura Landolfi, Margherita Brindisi, Valentina Onnis, Federica Moraca, Bruno Catalanotti

{"title":"Novel fatty acid amide hydrolase (FAAH) inhibitors: a patent review from 2015 to 2025.","authors":"Laura Landolfi, Margherita Brindisi, Valentina Onnis, Federica Moraca, Bruno Catalanotti","doi":"10.1080/13543776.2026.2619515","DOIUrl":"10.1080/13543776.2026.2619515","url":null,"abstract":"Introduction: Over the past decade, significant efforts have been made to develop and patent selective fatty acid amide hydrolase (FAAH) inhibitors with favorable pharmacokinetic and safety profiles to modulate pain, inflammation, and neurological disorders. Recently, attention has shifted toward dual inhibitors that combine FAAH inhibition with other targets, such as COXs, MAGL, and sEH, aiming to improve therapeutic outcomes. This review highlights the most significant patents from the last 10 years in this evolving field of research.Areas covered: Patents of selective and nonselective FAAH inhibitors published from 2015 to 2025. Patent searches were conducted on Espacenet, WIPO (World Intellectual Property Organization), and Google Patents databases, while literature search was performed using the Artificial Intelligence (AI) visual tools Connected Papers and Research Rabbit.Expert opinion: The search for novel and clinically relevant FAAH inhibitors starts with newly disclosed chemical entities. However, reducing translation gaps also requires advances in identifying key biomarkers and developing relevant animal models that mimic target diseases. Additionally, disclosing of innovative chemical templates, including those for allosteric modulation of FAAH, and the identification of suitable and innovative multitarget directed ligands will likely establish FAAH inhibitors as a validated therapeutic option for several diseases.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"279-297"},"PeriodicalIF":4.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0